Chemotherapy‐induced peripheral neuropathy among patients with ovarian cancer

2020 ◽  
Vol 149 (3) ◽  
pp. 303-308 ◽  
Author(s):  
Lin Jin ◽  
Yu Zhang ◽  
Wenqing Yang
Keyword(s):  
Ovarian Cancer ◽  
Peripheral Neuropathy

scholarly journals Small extracellular vesicles ameliorate peripheral neuropathy and enhance chemotherapy of oxaliplatin on ovarian cancer

2021 ◽  
Vol 10 (5) ◽  
Author(s):  
Yi Zhang ◽  
Chao Li ◽  
Yi Qin ◽  
Pasquale Cepparulo ◽  
Michael Millman ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Peripheral Neuropathy ◽  
Extracellular Vesicles

Phase II trial of the novel epothilone ZK-EPO in patients with platinum resistant ovarian cancer

2007 ◽  
Vol 25 (18_suppl) ◽  
pp. 5527-5527 ◽  
Author(s):  
G. J. Rustin ◽  
N. S. Reed ◽  
G. Jayson ◽  
J. A. Ledermann ◽  
M. Adams ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Peripheral Neuropathy ◽  
Phase Ii ◽  
Phase Ii Trial ◽  
Sensory Neuropathy ◽  
Significant Activity ◽  
Good Tolerability ◽  
Efficacy Analysis ◽  
Platinum Resistant ◽  
Ovarian Cancer Cell Lines

5527 Background: The rationally designed, fully synthetic epothilone ZK-EPO has demonstrated significant activity against ovarian cancer cell lines. The results of the first completed phase I study (one 30-min infusion q3w) indicated good tolerability, with peripheral neuropathy as the most common toxicity; signs of activity, including objective responses, were reported. A randomised phase II trial was performed to determine the efficacy, safety and tolerability of 2 infusion durations in patients with platinum-resistant ovarian cancer. Methods: Eligible patients were at first or second relapse, had a platinum-free interval of <6 months, and disease evaluable by RECIST or, if not measurable, by CA125 (GCIG criteria). Patients were randomised to receive 3-hour or 30-min infusions of 16 mg/m2 ZK- EPO administered 3-weekly. Simon’s two-step design was used; 13–34 patients were to be accrued per arm. An arm would be continued if at least 2/13 patients responded. The drug would be considered efficacious if ≥6/34 patients responded. Results: To date, 63 patients have entered the study (accrual completed November 2006). Data is currently available on the 30 patients in step 1. Four patients were excluded from efficacy analysis due to tumor histology (clear or mucinous), as per protocol. 24 patients were taxane pre-treated. 4/13 patients responded in the 3-hour arm so accrual continued; in the 30-min arm 1/13 responded. A total of 101 infusions were administered to patients in step 1. The most common drug-related toxicity >grade 1 in the 3-hour and 30-min arm was grade 2–3 peripheral sensory neuropathy (3-hour: 9/15 patients, 30 min: 5/15 patients). Two patients withdrew because of neuropathy, both in the 3-hour arm. Other drug-related toxicities >grade 1 occurring in >1 patient were fatigue (n=3), arthralgia (n=3), nausea (n=3) and lethargy (n=2). Conclusion: Preliminary results indicate that ZK-EPO, administered as a 3-hour infusion at a dose of 16 mg/m2, has promising activity against platinum-resistant ovarian cancer. Updated response data on all patients will be presented. Peripheral neuropathy currently appears to be the only noteworthy toxicity of ZK-EPO. [Table: see text]

A comparison of monthly symptom reports for older (≥ 70 years) versus younger (< 70 years) women with recurrent ovarian cancer over 1 year.

2015 ◽  
Vol 33 (29_suppl) ◽  
pp. 85-85 ◽  
Author(s):  
Premal H. Thaker ◽  
Susan M. Sereika ◽  
Janet Arida ◽  
Robert P. Edwards ◽  
Heidi Donovan
Keyword(s):  
Ovarian Cancer ◽  
Peripheral Neuropathy ◽  
Sleep Disturbances ◽  
Recurrent Ovarian Cancer ◽  
Age Group ◽  
Linear Quadratic ◽  
Eligibility Criteria ◽  
Change Over Time ◽  
Patient Reported ◽  
Over Time

85 Background: Approximately 30% of ovarian cancer patients are 70 or older at diagnosis. Evidence to guide treatment in this age group is limited in the recurrent setting due to clinician concerns about toxicities and quality of life. Evidence based on patient-reported outcomes is scarce. The objective of this exploratory analysis is to compare patient-reported symptoms for women with recurrent ovarian cancer > age 70 vs. < age 70. Methods: Ancillary analysis of data from a 3-arm web-based symptom management RCT (NR010735; GOG-259). Eligibility criteria included recurrent or persistent ovarian, fallopian, or primary peritoneal cancer; experiencing 3 or more cancer or treatment-related symptoms. 497 women were accrued; of those, 60 (12%) were > age 70. Monthly severity data for 11 cancer- and treatment-symptoms rated “at their worst in the past week” on a 0 to 10 Likert-type scale are included in this analysis. Time (linear, quadratic, and cubic), age (young vs. old), and time by age group interactions were evaluated using random coefficient modeling for each of the symptoms over 12 months. Results: In general, the severity of these selected symptoms declined significantly (p < .05) either linearly (memory problems and anxiety) or nonlinearly (fatigue, pain, constipation, peripheral neuropathy, nausea, lack of appetite, depression, and sleep disturbances) over time, except for vomiting which did not demonstrate a significant change over time. Age effects or age by time interactions (significant, p < .05, or a trend, .05 < = p < .10) were found for pain, constipation, peripheral neuropathy, vomiting, and sleep disturbances, with generally higher initial values for younger ( < = 70 years) women for pain and sleep disturbances and higher overall means for younger women for vomiting. For constipation and peripheral neuropathy, the nonlinear change over time varied significantly by age group, with the decline over time being more precipitous for older women. Conclusions: A better understanding of the different propensity for symptoms based on age can help clinicians not only address them but also choose chemotherapies to minimize them.

Association of Met-BDNF allele with pre-existing peripheral neuropathy in breast cancer patients.

2017 ◽  
Vol 35 (15_suppl) ◽  
pp. e21702-e21702
Author(s):  
David Azoulay ◽  
Anca Leibovici ◽  
Rivka Sharoni ◽  
Hadassah Goldberg
Keyword(s):  
Breast Cancer ◽  
Ovarian Cancer ◽  
Peripheral Neuropathy ◽  
Cancer Patients ◽  
Sanger Sequencing ◽  
Treatment Protocol ◽  
Breast Cancer Patients ◽  
Allelic Discrimination ◽  
Extended Study

e21702 Background: We previously published preliminary results suggesting an association between the met-BDNF allele and vulnerability to paclitaxel-induced peripheral neuropathy (PIPN) in breast cancer patients. Here we present updated data obtained from our extended study. Methods: 35 patients; 34 women (33 with breast cancer and 1 with ovarian cancer) and one man (breast cancer) completed their follow-up. Peripheral neuropathy (PN) was assessed at diagnosis and along the treatment protocol, using the reduced version of Total Neuropathy Score (TNSr). Patients with TNSr≥2 at diagnosis were determined with pre-existing PN (Pre-PN). Allelic discrimination of BDNF polymorphism (rs6265) was determined by Sanger sequencing. Results: BDNF genotype Val/Val was found in 20 patients (57.14%), Val/Met in 15 patients (42.86%). No patient had the Met/Met genotype. 10 patients (28.57%) were diagnosed with Pre-PN, 3 of them with diabetic-related neuropathy. A higher incidences of the Met-BDNF allele was found in patients with Pre-PN as compared to patients with no Pre-PN (7/10 (70%) vs. 8/25 (32%) Val/Met in Pre-PN and no Pre-PN respectively, prob > ChiSq < 0.05). The three patients with diabetic related Pre-PN were genotyped Met-BDNF. The maximal TNSr scores developed by each patient during follow-up were higher in Met-BDNF patients compare to Val/Val patients. (Maximal TNSr mean ± SEM in Val/Val 4.80±0.62 vs. 7.73±1.34 in Val/Met BDNF, prob < t 0.04). No difference in the maximal TNSr scores between Met-BDNF and Val/Val patients were shown after excluding the patients with Pre-PN (Maximal TNSr mean ± SEM in Val/Val 5.05±0.78 vs. 5.25±0.62 in Val/Met BDNF, prob < t 0.44). Conclusions: Our data demonstrate an association between met-BDNF and Pre-PN. Higher maximal TNSr scores in our met-BDNF patients is generally the consequence of their higher Pre-PN.

High-dose cisplatin in hypertonic saline in refractory ovarian cancer.

1985 ◽  
Vol 3 (9) ◽  
pp. 1246-1250 ◽  
Author(s):  
R F Ozols ◽  
Y Ostchega ◽  
C E Myers ◽  
R C Young
Keyword(s):  
Ovarian Cancer ◽  
Peripheral Neuropathy ◽  
Cancer Patients ◽  
Stable Disease ◽  
Phase Ii Trial ◽  
Standard Dose ◽  
Salvage Chemotherapy ◽  
High Dose ◽  
Previously Treated ◽  
Dose Limiting Toxicity

Nineteen previously treated refractory ovarian cancer patients, including 17 who had received standard-dose cisplatin regimens, were treated in a phase II trial with high-dose cisplatin (40 mg/m2 daily for five days with cycles administered every 28 to 35 days). Objective responses were achieved in 6/19 (32%) patients while eight patients had minor responses or stable disease. The median duration of survival from the start of salvage chemotherapy was 12 months for all patients, and 16 months for responding patients. The dose-limiting toxicity was peripheral neuropathy with 37% of patients having severe paresthesias or ataxia. These results indicate that the dose of cisplatin may be an important factor in improving survival in ovarian cancer patients.

scholarly journals Course of chemotherapy-induced peripheral neuropathy and its impact on health-related quality of life among ovarian cancer patients: A longitudinal study

2018 ◽  
Vol 149 (3) ◽  
pp. 455-463 ◽  
Author(s):  
Cynthia S. Bonhof ◽  
Floortje Mols ◽  
M. Caroline Vos ◽  
Johanna M.A. Pijnenborg ◽  
Dorry Boll ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Ovarian Cancer ◽  
Longitudinal Study ◽  
Peripheral Neuropathy ◽  
Cancer Patients ◽  
Health Related Quality ◽  
Related Quality ◽  
Health Related

Cancer chemotherapy: ▾ carboplatin v cisplatin

1987 ◽  
Vol 25 (17) ◽  
pp. 67-68
Keyword(s):  
Ovarian Cancer ◽  
Bone Marrow ◽  
Peripheral Neuropathy ◽  
Cancer Chemotherapy ◽  
Clinical Studies ◽  
Renal Damage ◽  
Bone Marrow Suppression ◽  
Severe Vomiting ◽  
Equal Efficacy

Carboplatin (Paraplatin – Bristol Myers) is an analogue of cisplatin, intended to offer equal efficacy with less toxicity. Cisplatin is very effective in the treatment of testicular and ovarian cancer and several other malignancies, but it is also very toxic. It causes peripheral neuropathy, auditory and renal damage, severe vomiting and mild bone marrow suppression.1,2 in early clinical studies, carboplatin appeared much less nephrotoxic and neurotoxic than cisplatin, and less emetic.3 How has it turned out on further evaluation?4

Sign in / Sign up

Export Citation Format

Share Document